Upstream Bio (NASDAQ:UPB - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Upstream Bio to post earnings of ($0.62) per share for the quarter.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($6.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($6.38). The firm had revenue of $0.61 million for the quarter, compared to analysts' expectations of $0.83 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Upstream Bio Price Performance
Shares of NASDAQ UPB traded up $0.86 during midday trading on Thursday, hitting $11.11. 74,528 shares of the company traded hands, compared to its average volume of 242,414. Upstream Bio has a 12-month low of $9.29 and a 12-month high of $29.46. The firm has a 50-day moving average of $16.86.
Analyst Ratings Changes
UPB has been the topic of a number of analyst reports. JPMorgan Chase & Co. started coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set an "overweight" rating and a $38.00 target price on the stock. William Blair initiated coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They issued an "outperform" rating for the company. Piper Sandler assumed coverage on Upstream Bio in a report on Tuesday, November 5th. They set an "overweight" rating and a $75.00 target price on the stock. Finally, TD Cowen assumed coverage on Upstream Bio in a research report on Tuesday, November 5th. They set a "buy" rating for the company.
Check Out Our Latest Research Report on UPB
Upstream Bio Company Profile
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
